Skip to main content
  • Home
  •  Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches

Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches

Topic:
  • Amyloidosis
  • Heart Failure

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
No ratings

Overview

This micro-learning series focuses on the forefront of cardiac amyloidosis, a rapidly advancing field in healthcare. Providing a focused and tailored update for key healthcare practitioners seeking to enhance their understanding of the latest developments in the diagnosis and treatment of cardiac amyloidosis and its consequences. Throughout this series, esteemed faculty delve into the intricate nature of amyloidosis, offering insights into the evolving management practices in cardiac amyloidosis. This educational journey navigates the nuances of diagnosing cardiac amyloidosis, emphasising the ability to distinguish between various types of the disease, addressing common pitfalls in assessment and underscoring the importance of a collaborative interdisciplinary approach.

Support Statement

This programme is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the creation of the content.

Disclosure

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 3 years and upcoming 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable. 

 

The session, ‘Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits. 

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity.

EBAC® holds agreements on:

  • Mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada.
  • CME credit conversion with the American Medical Association (AMA).

 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of participation in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Instruction to Participants

There is no fee for taking part in this online learning activity. 

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame. 

 

To complete the course and claim certification participants must: 

 

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions. 
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion. 

Target Audience

  • Cardiologists
  • Imaging Specialists
  • Electrophysiologists
  • Primary Care Practitioners
  • Haematologists
  • Cardiac Nurse Practitioners

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Understand the nature of amyloidosis and its effects on various organs, particularly the heart
  • Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
  • Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
  • Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
  • Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
  • Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team

Module

Title

Duration

Speakers

Part 1 An Overview of Amyloidosis: Cardiac and Non-Cardiac Features 5m 35s Philip Hawkins
Part 2 Cardiac Magnetic Resonance (CMR) in Amyloidosis 6m 16s Marianna Fontana
Part 3 Light Chain (AL) Amyloidosis: The Importance of Early Diagnosis 7m 10s Paolo Milani
Part 4 Hereditary TTR amyloidosis: Diagnosis and Treatment 7m 17s Julian Gillmore
Part 5 How to Manage a Person With a Mutant TTR Gene and No Symptoms? 9m 2s Laura Obici
Part 6 Diagnosing Wild-Type TTR Amyloidosis (ATTRwt) 6m 56s Pablo Garcia-Pavia
Part 7 Cardiac Amyloidosis: Non-pharmacologic Therapy (ICD Use) 5m 35s Carol Whelan
Part 8 Clinical Trials in Cardiac Amyloidosis: Targeting the Precursor Protein 4m 15s Julian Gillmore
Part 9 PYP and DPD Imaging for the Diagnosis of Transthyretin Amyloidosis 6m 13s Philip Hawkins
Part 10 Echocardiography in Amyloidosis 6m 7s Carol Whelan
Part 11 Cardiac Amyloidosis: Cardiology and the Multidisciplinary Team 6m 27s Finn Gustafsson
Part 12 Should I Set Up My Own Amyloidosis Program? 10m 13s Márcia Waddington-Cruz
Part 1.

An Overview of Amyloidosis: Cardiac and Non-Cardiac Features

Duration: 5m 35s

Speakers: Philip Hawkins

Part 2.

Cardiac Magnetic Resonance (CMR) in Amyloidosis

Duration: 6m 16s

Speakers: Marianna Fontana

Part 3.

Light Chain (AL) Amyloidosis: The Importance of Early Diagnosis

Duration: 7m 10s

Speakers: Paolo Milani

Part 4.

Hereditary TTR amyloidosis: Diagnosis and Treatment

Duration: 7m 17s

Speakers: Julian Gillmore

Part 5.

How to Manage a Person With a Mutant TTR Gene and No Symptoms?

Duration: 9m 2s

Speakers: Laura Obici

Part 6.

Diagnosing Wild-Type TTR Amyloidosis (ATTRwt)

Duration: 6m 56s

Speakers: Pablo Garcia-Pavia

Part 7.

Cardiac Amyloidosis: Non-pharmacologic Therapy (ICD Use)

Duration: 5m 35s

Speakers: Carol Whelan

Part 8.

Clinical Trials in Cardiac Amyloidosis: Targeting the Precursor Protein

Duration: 4m 15s

Speakers: Julian Gillmore

Part 9.

PYP and DPD Imaging for the Diagnosis of Transthyretin Amyloidosis

Duration: 6m 13s

Speakers: Philip Hawkins

Part 10.

Echocardiography in Amyloidosis

Duration: 6m 7s

Speakers: Carol Whelan

Part 11.

Cardiac Amyloidosis: Cardiology and the Multidisciplinary Team

Duration: 6m 27s

Speakers: Finn Gustafsson

Part 12.

Should I Set Up My Own Amyloidosis Program?

Duration: 10m 13s

Speakers: Márcia Waddington-Cruz

Speaker

Philip Hawkins

Philip Hawkins

University College London and The Royal Free Hospital, London, UK

Prof Philip Hawkins is a Professor of Medicine at University College London and Clinical Director of the NHS National Amyloidosis Centre at The Royal Free, London, UK. He is a rheumatologist and clinical scientist renowned for his studies on amyloidosis.

View full profile
Marianna Fontana​

Marianna Fontana

University College London, London, UK

Prof Marianna Fontana is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, London, UK.

View full profile
Paolo Milani

Paolo Milani

University of Pavia, Pavia, IT

Dr Paolo Milani works as a consultant in the Pavia Amyloidosis Research and Treatment Center at the Foundation “IRCCS Policlinico San Matteo” in Pavia, Italy.

View full profile

Julian Gillmore

University College London, London, UK

Julian Gillmore gained his medical degree at University of London. He trained in nephrology and undertook MD and PhD degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis.

View full profile

Laura Obici

I.R.C.C.S. San Matteo Polyclinic, Pavia, IT

Laura Obici practices in Pavia, Italy. Dr Obici and is regarded in 16 conditions. Her top areas of expertise are Transthyretin Amyloidosis, Primary Amyloidosis, Familial Transthyretin Amyloidosis, Cardiac Amyloidosis, and Tissue Biopsy.

View full profile
Pablo Garcia-Pavia

Pablo Garcia-Pavia

View full profile
Carol J. Whelan

Carol Whelan

In October 2009, the Royal Free London NHS Foundation Trust hired Dr. Carol Whelan as a consultant cardiologist with expertise in imaging, heart failure, and cardiac amyloidosis.

View full profile
Finn Gustafsson

Finn Gustafsson

Department of Cardiology, Rigshospitalet, University of Copenhagen, DK

Finn Gustafsson, MD, PhD, DMSci, is a professor of cardiology at the University of Copenhagen and medical director of the advanced heart failure, transplantation and MCS program at Rigshospitalet in Copenhagen, Denmark.

View full profile
1.00 EBAC

Related Courses

The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM
  • 1.00 EBAC

Learning objectives

  • Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends
  • List red flags indicating the presence of ATTR amyloidosis
  • Identify patients who should undergo detailed diagnosis work-up or referral
  • List the advantages of emerging classes of agents being evaluated in ATTR-CM
See more
Challenges in ATTR Amyloidosis: An Expert Debate
  • 1.00 EBAC

Learning objectives

  • Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
  • Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
  • Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
  • Recall the limitations of existing therapies for ATTR-CM
  • List the advantages of emerging classes of agents being evaluated in ATTR-CM
See more